J. Goldman & Co’s Cardlytics CDLX Stock Holding History

J. Goldman & Co’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,872	Closed	-$2.15M	–	272
2018 Q4	$2.15M	Buy	+19,872	New	+$3.35M	0.17%	137

Other funds holding CDLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CPV

Canaan Partners VIII Westport, Connecticut $31M AUM 45.38% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

J. Goldman & Co's CDLX Position: Q1 2019 in Review

J. Goldman & Co sold out of Cardlytics (CDLX) in Q1 2019, closing a stake of 19,872 shares — an estimated $2.15M sold.

J. Goldman & Co first reported a position in CDLX in Q4 2018 and held it in 1 quarter. The position peaked at $2.15M in Q4 2018. 62 funds tracked by Wall St. Rank hold CDLX as of Q1 2019.

J. Goldman & Co reported no remaining Cardlytics position as of Q1 2019 after selling out during the quarter.
J. Goldman & Co sold 19,872 Cardlytics shares in Q1 2019, an estimated $2.15M.
J. Goldman & Co first reported a position in Cardlytics in Q4 2018 and held it in 1 quarter.
J. Goldman & Co's Cardlytics position peaked at $2.15M in Q4 2018.
62 funds tracked by Wall St. Rank held Cardlytics as of Q1 2019.

Based on J. Goldman & Co's 13F filing for Q1 2019, filed 14 May 2019.